Stroke Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025

Published: Jan 2022 Pages: 120 SKU: IRTNTR72099

The stroke therapeutics market share is expected to increase by USD 1.54 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5.00%.

This stroke therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers stroke therapeutics market segmentation by type (ischemic stroke and hemorrhagic stroke) and geography (North America, Europe, Asia, and ROW). The stroke therapeutics market report also offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Pfizer Inc., and Sanofi SA among others.

What will the Stroke Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Stroke Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Stroke Therapeutics Market: Key Drivers, Trends, and Challenges

The high-risk factors for stroke is notably driving the stroke therapeutics market growth, although factors such as high level of genericization in the market may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the stroke therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Stroke Therapeutics Market Driver

One of the key factors driving growth in the stroke therapeutics market is the high-risk factors for stroke. Stroke is the second-leading cause of death globally among adults. Strokes are responsible for two-thirds of deaths among people living in developing countries. The high prevalence of stroke is mainly attributed to the increase in the incidence of ischemic strokes and hemorrhagic strokes, mainly because of the increasing presence of high-risk factors over the years. The increase in the risk factors for strokes is one of the major drivers for the growth of the market. The major risk factors are high blood pressure, high cholesterol levels and obesity, heart diseases, diabetes, sickle cell disease, smoking, and excessive alcohol consumption. The presence of high-risk factors for stroke is expected to increase its prevalence globally, thereby driving the market growth during the forecast period.

Key Stroke Therapeutics Market Trend

The development of novel therapies is another factor supporting the stroke therapeutics market share growth. The global stroke therapeutics market is expected to benefit from the development of novel therapies, such as stem cell therapies. Owing to the high prevalence of stroke, there is a huge need for safe and innovative novel therapies to treat stroke. Therefore, several companies are developing novel drugs for the treatment of stroke. The development of stem cell therapy will have a major impact on upcoming stroke therapeutics, as it has fewer side effects and regenerative properties. For instance, Athersys is developing MultiStem. It is a cell therapy regenerative medicine product currently in Phase III clinical development for the treatment of ischemic strokes. MultiStem has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage. The development of such novel therapies with fewer side effects is expected to contribute to market growth during the forecast period. 

Key Stroke Therapeutics Market Challenge

The high level of genericization in the market will be a major challenge for the stroke therapeutics market during the forecast period. Owing to the patent expiry of several branded drugs, pharmaceutical companies have entered the market with low-cost generics, which have affected the sales of high-cost branded drugs. For instance, after CRESTOR (rosuvastatin calcium from AstraZeneca) lost its patent exclusivity, several companies received approvals for generic versions of the drug. In May 2019, Shandong Bechem Chemicals Co. Ltd. received an abbreviated new drug application (ANDA) approval for generic rosuvastatin calcium. Moreover, tentative approvals for and market entry of the generic versions of many branded products are expected after their patent expiry. The growing dominance of low-cost generics is expected to hamper the growth of the market during the forecast period by affecting the sales of, and consequently, the revenue from high-cost branded drugs.

This stroke therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global stroke therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the stroke therapeutics market during the forecast period.

Who are the Major Stroke Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Johnson and Johnson Inc.
  • Merck and Co. Inc.
  • Pfizer Inc.
  • Sanofi SA

 

This statistical study of the stroke therapeutics market encompasses successful business strategies deployed by the key vendors. The stroke therapeutics market is fragmented and the vendors are deploying growth strategies such as forming strategic alliances and acquisitions to compete in the market.

Product Insights and News

  • Amgen Inc. - The company offers stroke therapeutics named Repatha.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The stroke therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Stroke Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the stroke therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

  • Research and development (R&D) and drug discovery
  • Integration and product development
  • Manufacturing
  • Outbound logistics
  • Marketing and sales
  • Support activities
  • Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Stroke Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from North America during the forecast period. The US is the key market for stroke therapeutics in North America. Market growth in this region will be faster than the growth of the market in the European and ROW regions.

The high prevalence of the disease and recent product approvals will facilitate the stroke therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 impacted the clinical trials for stroke therapeutics in the region. Due to the outbreak, pharmaceutical companies shifted their focus mainly toward developing COVID-19 medicines and vaccines. However, a stroke is a critical disease that requires constant medications and clinical visits even during the pandemic. Also, since cases of COVID-19 have reduced in 2021, the focus on clinical trials for stroke therapeutics has increased. This will drive the market growth during the forecast period.

What are the Revenue-generating Type Segments in the Stroke Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The stroke therapeutics market share growth by the ischemic stroke segment will be significant during the forecast period. The growth of this segment is majorly driven by the high prevalence of strokes. High-risk factors, such as obesity, atherosclerosis, hypertension, and old age, are the major contributors to the growth of the segment during the forecast period. The growth of this segment is also expected to be driven by the robust development of the drug pipeline for this type of stroke. Novel therapies, such as MultiStem from Athersys and NA-1 from NoNO Inc. (NoNO), are expected to receive marketing approval. The availability of patient assistance programs for branded drugs by pharmaceutical manufacturers is expected to propel the growth of this segment during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the stroke therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Stroke Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 5.00%

Market growth 2021-2025

$ 1.54 billion

Market structure

Fragmented

YoY growth (%)

4.68

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Pfizer Inc., and Sanofi SA

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Stroke Therapeutics Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive stroke therapeutics market growth during the next five years
  • Precise estimation of the stroke therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the stroke therapeutics industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of stroke therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

***1. Executive Summary                         

               **1.1 Market Overview 

                              *Exhibit 01:  Key Finding 1

                              *Exhibit 02:  Key Finding 2

                              *Exhibit 03:  Key Finding 3

                              *Exhibit 04:  Key Finding 5

                              *Exhibit 05:  Key Finding 6

                              *Exhibit 06:  Key Finding 7

                              *Exhibit 07:  Key Finding 8

***2. Market Landscape                            

               **2.1 Market ecosystem             

                              *Exhibit 08:  Parent market

                              *Exhibit 09:  Market characteristics

               **2.2 Value chain analysis           

                              *Exhibit 10:  Value chain analysis: Pharmaceuticals

                              *2.2.1 Research and development (R&D) and drug discovery

                              *2.2.2 Integration and product development

                              *2.2.3 Manufacturing

                              *2.2.4 Outbound logistics

                              *2.2.5 Marketing and sales

                              *2.2.6 Support services

***3. Market Sizing                      

               **3.1 Market definition

                              *Exhibit 11:  Offerings of vendors included in the market definition

               **3.2 Market segment analysis  

                              *Exhibit 12:  Market segments

               **3.3 Market size 2020 

               **3.4 Market outlook: Forecast for 2020 - 2025 

                              *3.4.1 Estimating growth rates for emerging and high-growth markets

                              *3.4.2 Estimating growth rates for mature markets

                              *Exhibit 13:  Global - Market size and forecast 2020 - 2025 ($ million)

                              *Exhibit 14:  Global market: Year-over-year growth 2020 - 2025 (%)

***4. Five Forces Analysis                         

               **4.1 Five Forces Summary         

                              *Exhibit 15:  Five forces analysis 2020 & 2025

               **4.2 Bargaining power of buyers            

                              *Exhibit 16:  Bargaining power of buyers

               **4.3 Bargaining power of suppliers        

                              *Exhibit 17: Bargaining power of suppliers

               **4.4 Threat of new entrants     

                              *Exhibit 18:  Threat of new entrants

               **4.5 Threat of substitutes          

                              *Exhibit 19: Threat of substitutes

               **4.6 Threat of rivalry   

                              *Exhibit 20: Threat of rivalry

               **4.7 Market condition 

                              *Exhibit 21:  Market condition - Five forces 2020

***5. Market Segmentation by Type                    

               **5.1 Market segments

                              *The segments covered in this chapter are:

  • *Ischemic stroke
  • *Hemorrhagic stroke

                              *Exhibit 22:  Type - Market share 2020-2025 (%)

               **5.2 Comparison by Type          

                              *Exhibit 23:  Comparison by Type

               **5.3 Ischemic stroke - Market size and forecast 2020-2025         

                              *Exhibit 24:  Ischemic stroke - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 25:  Ischemic stroke - Year-over-year growth 2020-2025 (%)

               **5.4 Hemorrhagic stroke - Market size and forecast 2020-2025 

                              *Exhibit 26:  Hemorrhagic stroke - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 27:  Hemorrhagic stroke - Year-over-year growth 2020-2025 (%)

               **5.5 Market opportunity by Type          

                              *Exhibit 28:  Market opportunity by Type

***6. Customer landscape                        

                              *Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

               **6.1 Overview

                              *Exhibit 29:  Customer landscape

***7. Geographic Landscape                    

               **7.1 Geographic segmentation

                              *The regions covered in the report are:

  • *North America
  • *Europe
  • *Asia
  • *ROW

                              *Exhibit 30:  Market share by geography 2020-2025 (%)

               **7.2 Geographic comparison    

                              *Exhibit 31:  Geographic comparison

               **7.3 North America - Market size and forecast 2020-2025          

                              *Exhibit 32:  North America - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 33:  North America - Year-over-year growth 2020-2025 (%)

               **7.4 Europe - Market size and forecast 2020-2025         

                              *Exhibit 34:  Europe - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 35:  Europe - Year-over-year growth 2020-2025 (%)

               **7.5 Asia - Market size and forecast 2020-2025

                              *Exhibit 36:  Asia - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 37:  Asia - Year-over-year growth 2020-2025 (%)

               **7.6 ROW - Market size and forecast 2020-2025             

                              *Exhibit 38:  ROW - Market size and forecast 2020-2025 ($ million)

                              *Exhibit 39:  ROW - Year-over-year growth 2020-2025 (%)

               **7.7 Key leading countries        

                              *Exhibit 40:  Key leading countries

               **7.8 Market opportunity by geography

                              *Exhibit 41:  Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends                  

               **8.1 Market drivers      

                              *8.1.1 High-risk factors for stroke

                              *8.1.2 Growing geriatric population

                              *8.1.3 Strong pipeline

               **8.2 Market challenges              

                              *8.2.1 High level of genericization in the market

                              *8.2.2 Availability of substitutes

                              * 8.2.3 Unmet needs for anticoagulant reversal agents

                              *Exhibit 42:  Impact of drivers and challenges

               **8.3 Market trends      

                              *8.3.1 Development of novel therapies

                              *8.3.2 Increasing awareness about stroke

                              *8.3.3 TBI, a value-addition in AIS research

***9. Vendor Landscape                            

               **9.1 Overview

                              *Exhibit 43:  Vendor landscape

               **9.2 Landscape disruption         

                              *Exhibit 44:  Landscape disruption

                              *Exhibit 45:  Industry risks

***10. Vendor Analysis               

               **10.1 Vendors covered              

                              *Exhibit 46:  Vendors covered

               **10.2 Market positioning of vendors    

                              *Exhibit 47: Market positioning of vendors

               **10.3 Amgen Inc.

                              *Exhibit 48:  Amgen Inc. - Overview

                              *Exhibit 49:  Amgen Inc. - Business segments

                              *Exhibit 50:  Amgen Inc. - Key offerings

                              *Exhibit 51:  Amgen Inc. - Segment focus

               **10.4 AstraZeneca Plc 

                              *Exhibit 52:  AstraZeneca Plc - Overview

                              *Exhibit 53:  AstraZeneca Plc - Product and service

                              *Exhibit 54:  AstraZeneca Plc - Key offerings

               **10.5 Bayer AG             

                              *Exhibit 55:  Bayer AG - Overview

                              *Exhibit 56:  Bayer AG - Business segments

                              *Exhibit 57:  Bayer AG - Key offerings

                              *Exhibit 58:  Bayer AG - Segment focus

               **10.6 Boehringer Ingelheim International GmbH            

                              *Exhibit 59:  Boehringer Ingelheim International GmbH - Overview

                              *Exhibit 60:  Boehringer Ingelheim International GmbH - Business segments

                              *Exhibit 61:  Boehringer Ingelheim International GmbH - Key news

                              *Exhibit 62:  Boehringer Ingelheim International GmbH - Key offerings

                              *Exhibit 63:  Boehringer Ingelheim International GmbH - Segment focus

               **10.7 Bristol Myers Squibb Co.

                              *Exhibit 64:  Bristol Myers Squibb Co. - Overview

                              *Exhibit 65:  Bristol Myers Squibb Co. - Product and service

                              *Exhibit 66:  Bristol Myers Squibb Co. - Key offerings

               **10.8 F. Hoffmann La Roche Ltd.

               **Exhibit 67:  F. Hoffmann La Roche Ltd. - Overview        

               **Exhibit 68:  F. Hoffmann La Roche Ltd. - Business segments      

               **Exhibit 69:  F. Hoffmann La Roche Ltd. - Key offerings 

               **Exhibit 70:  F. Hoffmann La Roche Ltd. - Segment focus             

               **10.9 Johnson and Johnson Inc.             

                              *Exhibit 72:  Johnson and Johnson Inc.  - Business segments

                              *Exhibit 73:  Johnson and Johnson Inc.  - Key offerings

               **10.10 Merck and Co. Inc.        

                              *Exhibit 75:  Merck and Co. Inc. - Overview

                              *Exhibit 76:  Merck and Co. Inc. - Business segments

                              *Exhibit 77:  Merck and Co. Inc. - Key offerings

                              *Exhibit 78:  Merck and Co. Inc. - Segment focus

               **10.11 Pfizer Inc.          

                              *Exhibit 79:  Pfizer Inc. - Overview

                              *Exhibit 80:  Pfizer Inc. - Business segments

                              *Exhibit 81:  Pfizer Inc. -Key news

                              *Exhibit 82:  Pfizer Inc. - Key offerings

                              *Exhibit 83:  Pfizer Inc. - Segment focus

               **10.12 Sanofi SA           

                              *Exhibit 84:  Sanofi SA - Overview

                              *Exhibit 85:  Sanofi SA - Business segments

                              *Exhibit 86:  Sanofi SA- Key news

                              *Exhibit 87:  Sanofi SA - Key offerings

                              *Exhibit 88:  Sanofi SA - Segment focus

***11. Appendix                           

               **11.1 Scope of the report         

                              *11.1.1 Market definition

                              *11.1.2 Objectives

                              *11.1.3 Notes and caveats

               **11.2 Currency conversion rates for US$            

                              *Exhibit 89:  Currency conversion rates for US$

               **11.3 Research Methodology   

                              *Exhibit 90:  Research Methodology

                              *Exhibit 91:  Validation techniques employed for market sizing

                              *Exhibit 92:  Information sources

               **11.4 List of abbreviations        

                              *Exhibit 93:  List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

PURCHASE FULL REPORT OF

stroke therapeutics market

QUICK BUY

Key Questions Answered

  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis